Eli Lilly & Co. (LLY) Announces US FDA accepts supplemental New Drug Application for Jardiance® for children 10 years and older with type 2 diabetes

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to Eli Lilly & Co. (LLY) Announces US FDA accepts supplemental New Drug Application for Jardiance® for children 10 years and older with type 2 diabetes

J.P. Morgan sees recent Eli Lilly (LLY) weakness as opportunity ahead of Donanemab Ph3 Data

March 9, 2023 1:01 PM EST

J.P. Morgan reiterated an Overweight rating and a $400.00 price target on Eli Lilly and Company (NYSE: LLY) ahead of the upcoming release of the donanemab ph3 data.

Analyst Chris Schott wrote in a note, Following recent LLY weakness, we have been receiving a number of questions on the story and wanted to provide our updated thoughts on upcoming donanemab ph3 data as well as... More